406 chapter 7 Table 8. Mixed linear modelling of changes in ThyPRO scores Baseline (Intercept) Change over time (slope) Assessment, scale B SE p (between group)* B SE p (within group)† p (between group)§ ThyPRO Goitre Symptoms Malignant 26.3 4.2 0.73 -2.1 1.3 0.11 0.66 Benign 27.9 2.5 ref -2.7 0.8 <0.001 ref Active surveillance 19.3 3.3 0.09 -0.3 0.9 0.72 0.11 Hyperthyroid Symptoms Malignant 13.1 3.7 0.66 1.1 1.1 0.32 0.67 Benign 15.0 2.4 ref 1.6 0.6 0.01 ref Active surveillance 16.6 3.4 0.74 -0.4 0.9 0.68 0.11 Hypothyroid Symptoms Malignant 20.4 4.9 0.99 0.7 1.4 0.60 0.92 Benign 20.5 3.2 ref 0.9 0.9 0.31 ref Active surveillance 22.4 5.4 0.77 -0.3 1.2 0.82 0.47 Eye Symptoms Malignant 13.2 3.9 0.64 0.2 1.1 0.90 0.47 Benign 11.2 2.2 ref 1.0 0.6 0.12 ref Active surveillance 13.3 3.9 0.65 -0.3 0.8 0.74 0.31 Tiredness Malignant 29.8 4.8 0.20 0.9 1.3 0.48 0.55 Benign 37.1 3.1 ref 0.9 1.5 0.99 ref Active surveillance 31.7 4.4 0.38 -0.5 1.1 0.65 0.77 Cognitive Impairment Malignant 17.0 4.5 0.73 1.2 1.2 0.34 0.51 Benign 18.7 2.8 ref 2.1 0.8 0.01 ref Active surveillance 16.3 4.5 0.66 0.0 0.9 0.99 0.15 Anxiety Malignant 27.9 4.4 0.39 -2.5 1.3 0.05 0.66 Benign 32.5 3.0 ref -1.8 0.9 0.04 ref Active surveillance 20.4 4.6 0.04 -0.4 1.1 0.72 0.38 Depressivity Malignant 26.0 4.7 0.75 -0.6 1.3 0.66 0.51 Benign 27.7 3.0 ref 0.3 0.8 0.66 ref Active surveillance 20.0 4.1 0.19 -0.2 1.0 0.89 0.74 Emotional Susceptibility Malignant 26.4 4.6 0.49 -0.4 1.2 0.74 0.48 Benign 29.9 2.9 ref 0.6 0.8 0.46 ref Active surveillance 19.3 4.0 0.06 0.9 0.9 0.35 0.83 Social Impairment Malignant 11.8 4.1 0.71 0.4 1.2 0.76 0.46 Benign 10.0 2.8 ref 1.5 0.8 0.09 ref Active surveillance 11.0 3.6 0.85 -1.0 1.1 0.38 0.11 Impaired Daily Life Malignant 16.6 5.1 0.68 0.5 1.5 0.75 0.8 Benign 14.4 3.1 ref 0.9 1.0 0.34 ref Active surveillance 10.2 3.3 0.48 -1.2 1.0 0.25 0.24 Impaired Sex Life Malignant 18.9 6.5 0.65 0.6 1.9 0.78 0.96 Benign 22.3 4.2 ref 0.7 1.3 0.61 0.96 Active surveillance 23.9 7.1 0.85 -1.9 1.8 0.30 0.31 Cosmetic Complaints Malignant 11.1 4.2 0.81 0.6 1.2 0.64 0.38 Benign 12.3 2.8 ref 1.9 0.8 0.02 ref Active surveillance 12.3 3.6 1 -0.5 1.1 0.67 0.14 Negative Influence on QoL Malignant 30.3 6.8 0.90 -2.4 2.1 0.27 0.82 Benign 31.2 4.7 ref -2.9 1.5 0.05 (n.s.) 0.82 Active surveillance 22.3 6.0 0.30 -3.0 1.8 0.10 1 ThyPRO Composite QoL Malignant 24.3 4.0 0.50 -0.2 1.0 0.82 0.68 Benign 27.2 2.3 ref 0.2 0.6 0.73 ref Active surveillance 19.9 3.3 0.12 -0.3 0.7 0.64 0.64
RkJQdWJsaXNoZXIy MTk4NDMw